BioNTech gains rights to 4SC Discovery's potential cancer drugs

12/18/2012 | Genetic Engineering & Biotechnology News

4SC Discovery granted Germany-based BioNTech exclusive rights to market and commercialize its early-stage small molecule toll-like receptor agonists as immunotherapies for cancer. The research and licensing deal entitles 4SC to about $3.3 million upfront plus milestone and royalties. "Our goal is now to speed up and jointly develop a novel breakthrough therapy toward the market addressing the high medical need in the exciting field of cancer immunotherapy," 4SC Discovery Managing Director Daniel Vitt said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA